Free Access
Med Sci (Paris)
Volume 29, Number 10, Octobre 2013
Page(s) 836 - 839
Section Nouvelles
Published online 18 October 2013
  1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957 ; 147 : 258–267. [CrossRef] [PubMed] [Google Scholar]
  2. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008 ; 17 : 394–399. [CrossRef] [PubMed] [Google Scholar]
  3. Odorizzi PM, Wherry EJ. Immunology. An interferon paradox. Science 2013 ; 340 : 155–156. [CrossRef] [PubMed] [Google Scholar]
  4. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013 ; 340 : 207–211. [CrossRef] [PubMed] [Google Scholar]
  5. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013 ; 340 : 202–207. [CrossRef] [PubMed] [Google Scholar]
  6. Bolen CR, Robek MD, Brodsky L, et al. The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response. J Interferon Cytokine Res 2013 ; 33 : 15–23. [CrossRef] [PubMed] [Google Scholar]
  7. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008 ; 105 : 7034–7039. [CrossRef] [Google Scholar]
  8. Gringeri A, Musicco M, Hermans P, et al. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1–infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999 ; 20 : 358–370. [CrossRef] [PubMed] [Google Scholar]
  9. Sedaghat AR, German J, Teslovich TM, et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 2008 ; 82 : 1870–1883. [CrossRef] [PubMed] [Google Scholar]
  10. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013 ; 65 : 1011–1021. [CrossRef] [PubMed] [Google Scholar]
  11. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012 ; 64 : 3666–3676. [CrossRef] [PubMed] [Google Scholar]
  12. Tcherepanova I, Curtis M, Sale M, et al. Results of a randomized placebo controlled phase study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Berlin Annual European Congress on Rheumatology-EULAR, 2012. [Google Scholar]
  13. Wang B, Higgs BW, Chang L, et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody. Clin Pharmacol Ther 2013 ; 93 : 483–492. [CrossRef] [PubMed] [Google Scholar]
  14. Terrier B, Mouthon L. Lupus érythémateux systémique. Traitements par anticorps monoclonaux et molécules recombinantes. Med Sci (Paris) 2013 ; 29 : 65–73. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  15. Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2013 (sous presse). [Google Scholar]
  16. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum 2013 ; 65 : 447–456. [CrossRef] [PubMed] [Google Scholar]
  17. Bensussan A, Bizzini B, Pouletty P, Gallo R, Zagury D. Les kinoïdes. Med Sci (Paris) 2008 ; 24 : 306–313. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.